Search the Newsreel

Earnings Flash (PYR.TO) PyroGenesis Inc. Reports Q2 Revenue C$4.4M

Price to earnings forward of Spyre Therapeutics, Inc – DUS:3920

This article provides financial information for Spyre Therapeutics, Inc. trading on the Dusseldorf Stock Exchange under the ticker DUS:3920. It specifically mentions the "Price to earnings forward" metric but does not display any actual values, indicating the market is closed with no trades. The …

PyroGenesis Delivers 47% Q2 Revenue Surge and Expands Titanium Powder Business

PyroGenesis Announces Second Quarter 2026 Results: Revenue of $4.4 Million, Up 47% Year-Over-Year for Best Q2 Since 2022

First-half 2026 revenue has already surpassed the first nine months of 2025.Advancement of major projects drives Q2 revenue.Backlog of $40.0 million. MONTREAL, Aug. 06, 2026 (GLOBE NEWSWIRE) -- PyroGenesis Inc. (“PyroGenesis” or “the Company”) (TSX: PYR) (OTCQX: PYRGF) (FRA: 8PY1), a leader in ultra-high …

Cameron Turtle, Spyre Therapeutics CEO, sells $1.43m in stock

Cameron Turtle, CEO of Spyre Therapeutics (NASDAQ:SYRE), sold 15,000 shares of company stock worth over $1.43 million on August 3, 2026, as part of a pre-arranged trading plan. Despite these insider sales, the stock has seen a significant 554% gain over the past year …

Spyre Therapeutics (SYRE) CFO sells 7,500 shares after option exercise

Spyre Therapeutics (SYRE) CFO Scott L. Burrows exercised stock options for 7,500 shares at $14.50 each and subsequently sold all 7,500 shares in three transactions at weighted average prices between $95.21 and $97.10. These transactions were executed pursuant to a Rule 10b5-1 trading plan …

Spyre Therapeutics (SYRE) CEO trades 15,000 shares under 10b5-1 plan

Spyre Therapeutics CEO Cameron Turtle sold 15,000 shares of common stock on August 3, 2026, across five open-market transactions. These sales were conducted under a Rule 10b5-1 trading plan adopted in June 2025, with weighted average prices ranging from $93.97 to $97.46 per share. …

Spyre Therapeutics, Inc. Stock 12‑Month Price Target Raised to $119.43, Implies 14% Upside

Analysts have raised the average 12-month price target for Spyre Therapeutics, Inc. (SYRE) stock to $119.43 from $105.79, implying a potential upside of 14% based on the August 4th closing price. The consensus rating from 16 analysts remains a "Buy," with 15 Buys and …

SPYRE THERAPEUTICS INC : RAYMOND JAMES RAISES TARGET PRICE TO $121 FROM $88

Raymond James has increased its target price for SPYRE THERAPEUTICS INC (SYRE.O) to $121 from $88. This information comes from a Reuters report published on August 5, 2026. The article's content reflects only the author's opinion and is not intended as investment advice.

SYRE's Q2 Loss Narrower Than Expected, Pipeline Progresses

Spyre Therapeutics (SYRE) reported a Q2 2026 loss of 36 cents per share, which was narrower than the estimated 71 cents. The company, which has no marketed products, saw its operating expenses decrease slightly due to gains from the sale of an in-process R&D …

Spyre Therapeutics, Inc. Q2 2026: Net loss $36.2M, EPS $(0.36) — 10-Q Summary

Spyre Therapeutics, Inc. reported a net loss of $36.2 million for Q2 2026, a slight improvement from the $36.7 million loss in Q2 2025, with diluted loss per share at $(0.36). The company had no product revenue, with results primarily influenced by R&D spending, …

Spyre Therapeutics (NASDAQ:SYRE) Posts Quarterly Earnings Results

Pyrophyte Acquisition Corp. II Revenue Breakdown – NYSE:PAII.U

Spyre Therapeutics (NASDAQ:SYRE) Sets New 52-Week High Following Strong Earnings

Press Release: Spyre Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Spyre Therapeutics reported its second-quarter 2026 financial results, which included cash and cash equivalents of $772.1 million. The company also provided a corporate update, highlighting progress in its clinical programs for IBD and outlining its financial outlook for the coming year.

Spyre expects six Phase 2 trial readouts in 2026; cash totals $1.1B

Spyre Therapeutics reported Q2 2026 financial results, highlighting positive topline induction data for SPY001 and SPY002 in ulcerative colitis. The company completed enrollment for its Phase 2 SKYWAY basket trial and anticipates six proof-of-concept Phase 2 readouts in 2026. Spyre also reported $1.1453 billion …

Spyre Therapeutics stock hits 52-week high at 105.11 USD By Investing.com

Spyre Therapeutics (SYRE) stock has reached a new 52-week high of $105.11, marking a significant 517.49% increase over the past year and achieving a market capitalization of $9.23 billion. This surge is driven by strong investor confidence and positive phase 2 trial results for …

Spyre Therapeutics (SYRE) Earnings Date and Reports 2026 $SYRE

SYRE (NASDAQ: SYRE) insider schedules 30,000-share stock sale notice

SYRE insider Scott Burrows has filed a Form 144 notice to sell 30,000 shares of common stock through Morgan Stanley Smith Barney LLC on August 3, 2026, related to the exercise of stock options. The aggregate value of this planned sale is $2,949,900.00. The …

Spyre Therapeutics, Inc. $SYRE is Perceptive Advisors LLC's 7th Largest Position

PyroGenesis Inc. Revenue Breakdown – TSX:PYR

178,389 Shares in Spyre Therapeutics, Inc. $SYRE Acquired by First Trust Advisors LP

Spyre Therapeutics, Inc. $SYRE Shares Sold by Janus Henderson Group PLC

PyroGenesis Schedules 2026 Second Quarter Financial Results and Business Update Conference Call

MONTREAL, July 31, 2026 (GLOBE NEWSWIRE) -- PyroGenesis Inc. (“PyroGenesis” or “the Company”) (TSX: PYR) (OTCQX: PYRGF) (FRA: 8PY1), a leader in ultra-high temperature processes and engineering innovation, and a plasma-based technology provider to heavy industry & defense, announces today that it will host …

Spyre Therapeutics Inc (SYRE) Institutional Confidence

This article analyzes the institutional confidence in Spyre Therapeutics Inc (SYRE), highlighting its strong score of 10.00 within the Biotechnology & Medical Research industry. Institutional shareholding has increased by 19.72% quarter-over-quarter, with Fidelity Management & Research Company LLC and BlackRock Institutional Trust Company, N.A. …

Stempoint Capital LP Buys 135,229 Shares of Spyre Therapeutics, Inc. $SYRE

Papyrus Australia Ltd Revenue Breakdown – ASX:PPY

SYRE|Spyre Therapeutics Inc|Price:99.940|Chg%:-0.100

This article provides a comprehensive stock analysis of Spyre Therapeutics Inc. (SYRE), highlighting its relatively weak fundamentals but high growth potential, fair valuation, and strong institutional ownership. It details the company's clinical-stage biotechnology focus on inflammatory bowel disease (IBD) and other immune-mediated diseases, outlining …

Wolfe Research downgrades Spyre stock rating on valuation concerns By Investing.com

Wolfe Research downgraded Spyre Therapeutics (NASDAQ:SYRE) to Peerperform from Outperform due to valuation concerns, setting a fair value range of $96 to $113 per share. The firm noted that the stock is currently trading at $100, near its 52-week high, and expressed a lack …

Papyrus Australia (ASX:PPY) hits TBS milestones with just 2.1 quarters of funding left

Spyre Therapeutics Inc (SYRE) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Spyre Therapeutics Inc (SYRE), detailing its current stock price momentum, support and resistance levels, and insights from various technical indicators and moving averages. While the overall signal is Neutral according to technical analysis, the moving averages show …

Spyre Therapeutics Inc (SYRE) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Spyre Therapeutics Inc's (SYRE) dividend and stock split history. It indicates that SYRE has distributed no dividends over the past five years. The company did experience multiple "Merger 25→1" stock splits on September 7, 2023.

What's lifting Empyrean Energy (LSE:EME) among AIM smallcaps this week?

Sona Asset Management US LLC Invests $1.54 Million in Pyrophyte Acquisition Corp. II $PAII

Spyre Therapeutics Inc (SYRE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey attempts to provide a revenue breakdown for Spyre Therapeutics Inc (SYRE), including business segments, regional revenue, and profit contribution. However, the article states that relevant data for these categories have not yet been disclosed by the company. It therefore presents …

PAII|Pyrophyte Acquisition Corp II|Price:10.235|Chg%:+0.005

This article provides a detailed financial overview of Pyrophyte Acquisition Corp II (PAII), a blank check company. It includes current stock price, market capitalization, key financial figures, technical indicator analysis, and major shareholders. The company has not yet disclosed EPS or total revenue data, …